Progyny, Inc. (PGNY) - Stock Analysis
Last updated: Jun 21, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Healthcare services momentum with supportive fundamentals: record Q1 revenue of $328.5M, EPS beat, robust demand commentary, Progyny Select launch, and 8.8M shares repurchased since November. The stock surged about 45% over 21 trading days and 28% over the last five sessions, showing strong near-term follow-through.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Expansion ⢠Strong Cash Flow ⢠Moderate Leverage PGNY posted stronger Q1 profitability and solid cash flow with low leverage, but softer liquidity and a fair-to-rich valuation temper the outlook.
Price Behavior
Key Price Behavior Insights: ⢠Buyer defense ⢠Momentum cooling ⢠Breakout needed Support Level: $25.5-$25.7 Resistance Level: $26.6-$26.9 PGNY has a cautiously constructive short-term setup after a modest gain over the last month, but the recent drop from $26.91 to $26.08 shows fading momentum and leaves $26.6-$26.9 as the key breakout zone.
Sentiment & News
Key News Insights: ⢠Share Volatility ⢠Buyback Approval ⢠Human Guidance Progyny saw modest share volatility but offset it with a new $200 million buyback and reinforcing signals that demand for human-guided healthcare supports its care model.
AI Summary
PGNY should now be viewed less as a pure growth story and more as a cash-generative healthcare business whose upside depends on proving it can sustain low-double-digit organic growth after the large-client overhang; the improving margins, strong free cash flow, and $200M buyback argue the stock may be undervalued, but client concentration and shrinking cash cushion make execution the key risk.
Description
Progyny is a U.S. benefits management company that provides employer-sponsored fertility and family-building programs through tailored plan design, concierge-style member support, and a curated network of reproductive specialists. The company also offers an integrated pharmacy service for treatment medications and administers employer-funded surrogacy and adoption reimbursement programs. Incorporated in 2008 as Auxogyn and renamed Progyny in 2015, it is headquartered in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| May 11 | May 18 | PGNY | Progyny, Inc. | Healthcare services momentum with supportive fundamentals: record Q1 revenue of $328.5M, EPS beat, robust demand commentary, Progyny Select launch, and 8.8M shares repurchased since November. The stock surged about 45% over 21 trading days and 28% over the last five sessions, showing strong near-term follow-through. | Closed | +6.7% |